ST. PAUL, Minn., Feb. 5, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) Solventum today announced that its AI-powered radiology speech reporting solution, Solventum™ Fluency™ for Imaging, has ranked #1 in the 2025 Best in KLAS Awards—Software and Services Report for the fifth time.   Enabling faster, more accurate documentation, Solventum Fluency for Imaging helps radiologists save time, reduce burnout and improve efficiency by streamlining the reporting process. The technology integrates seamlessly into radio ...

Core Points - Solventum (NYSE: SOLV) will release its fourth quarter fiscal year 2024 financial results on February 27, 2025, after U.S. financial markets close [1] - Following the results release, management will host a webcast to discuss the results and the fiscal year 2025 outlook [1] - An Investor Day is planned for March 2025 in New York City to introduce the company's growth strategy and long-range financial plan [3] Earnings Webcast Details - The earnings webcast is scheduled for February 27, 2025, at 3:30 p.m. CST / 4:30 p.m. EST [2] - The webcast can be accessed via the company's investor relations website [2] - A replay of the webcast and additional financial disclosures will be available on the website [2] Company Overview - Solventum focuses on enabling better healthcare through innovative solutions at the intersection of health, material, and data science [4] - The company aims to create breakthrough innovations that improve patients' lives and empower healthcare professionals [4]

Company Performance and Potential - Solventum, formerly 3M's Health Care division, has high-quality businesses that delivered consistent performance within 3M, but its separation has not lived up to potential, with current performance significantly lower than when it was part of 3M [2][3] - Solventum's shares are currently trading at $69, but Trian believes the company could be worth $140 by year-end 2027 if it restores performance to historical levels [1][12] - Solventum's profit margins have declined nearly unprecedentedly since the spin-off, with consensus estimates expecting a 425bps decline in its first full standalone year, making it a bottom decile performer [6][8] Historical Context and Spin-Off Analysis - Prior to the spin-off, 3M research analysts estimated Solventum would be valued at $33 billion, implying a share price more than double its current trading price [3] - Solventum was 3M's best-performing business, consistently the fastest-growing and highest-margin division, but as an independent company, it has struggled to maintain growth and margins [7] - The average mid-to-large cap spin delivered approximately +125bps and +160bps of margin expansion in the first and third full year following separation, while Solventum's margins have declined significantly [6][8] Strategic Recommendations - Solventum should focus on improving operating performance, portfolio actions, and prudent capital allocation to enhance value creation [1] - Simplifying Solventum's portfolio, particularly by addressing non-core segments like Dental Solutions, Health Info Systems, and Purification & Filtration, could improve focus and execution [10][12] - Divestitures of non-core businesses could accelerate deleveraging and enable value-enhancing capital allocation decisions, including dividends, share repurchases, and bolt-on M&A [12] Long-Range Plan and Shareholder Engagement - Trian has initiated dialogues with Solventum's management and board, urging the company to act with urgency to reverse declines and communicate a more ambitious Long-Range Plan (LRP) [4] - The LRP should aim to restore Solventum's performance to historical levels, with growth targets of 3% to 4% organically and EBIT margins of 26%-27%, similar to its performance within 3M [12] - Trian believes historical performance levels and spin-related opportunities should frame Solventum's operating targets and broader strategy [12]

Core Insights - The T1D Fund has appointed Elizabeth Mily as CEO to enhance its leadership and investment strategy, focusing on type 1 diabetes (T1D) solutions [1][2] - Mily brings over 30 years of experience in pharma, healthcare investment banking, and strategic leadership, aiming to expand equity investments and partnerships [1][3] - The T1D Fund is positioned as an impact investor, working with biopharma to develop innovative therapies for T1D [4] Company Overview - The T1D Fund is an impact investment fund established in December 2016, dedicated to accelerating solutions for treating, preventing, and curing type 1 diabetes [5] - It is the first scaled, mission-driven venture impact fund focused on catalyzing the development of T1D cure-oriented therapies through equity investments [5] - The Fund collaborates with leading organizations like Breakthrough T1D and the Helmsley Charitable Trust to align its focus on T1D research [5] Leadership and Strategy - Elizabeth Mily previously served as Executive Vice President at Bristol Myers Squibb, overseeing company strategy and business development [3] - Mily's leadership is expected to enhance the T1D Fund's investment team and strategic partnerships, aiming to create an ecosystem for new therapies [1][4] - The Fund's unique position allows it to proactively engage with biopharma to bring innovative therapies to market [4]

Company Participation in Industry Events - Solventum executives will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 11:30 a.m. ET in New York, NY [1] - A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com [1] Company Overview - Solventum focuses on enabling better, smarter, and safer healthcare to improve lives [2] - The company pioneers innovations at the intersection of health, material, and data science to address customers' toughest challenges [2] - Solventum aims to empower healthcare professionals and improve patients' lives through breakthrough solutions [2]

Core Insights - Solventum (SOLV) has launched the 3M Clarity precision grip attachments for Clarity aligners, marking a significant advancement in aligner technology by addressing challenges in clear aligner treatments [1][2] - Despite the launch, SOLV's shares fell 3.1% on November 14, continuing a month-long downtrend, with a 1.7% decline since its IPO on April 1, 2024, while the industry declined by 11.2% and the S&P 500 gained 14.6% during the same period [2] Innovative Features of Clarity Attachments - The Clarity precision grip attachments eliminate the technique-sensitive and time-consuming attachment creation process, reducing variability in treatment [4] - These attachments are stain-resistant due to a blend of inorganic filler and organic resin, ensuring they remain discreet and aesthetically pleasing throughout treatment [5] - Clarity attachments simplify the clinical process by minimizing the risk of "composite flash," making the attachment process faster and less prone to error, leading to greater predictability in treatment outcomes [6] - The 3D printing manufacturing approach allows for customization to fit each patient's unique tooth anatomy [7] Market Potential and Future Development - The global clear aligners market was valued at approximately $3.8 billion in 2023 and is expected to exceed $28.15 billion by 2032, growing at a CAGR of 25.2% [8] - Key drivers for clear aligners demand include the rising prevalence of malocclusion, technological advancements, increased healthcare spending, and growing aesthetic demands in developing nations [9] - Solventum is pursuing regulatory approvals for Clarity attachments in other global markets and plans to enhance its product line with further advances in 3D printing and material science [7]

Clarity Precision Grip Attachments are fully cured, pre-loaded and precisely resemble the digital treatment plan after bonding ST. PAUL, Minn., Nov. 14, 2024 /PRNewswire/ -- This month, Solventum (NYSE: SOLV), formerly 3M Health Care, officially launched an anticipated innovation in aligner treatment, 3M™ Clarity™ Precision Grip Attachments. Available exclusively with 3M™ Clarity™ Aligners, Clarity Precision Grip Attachments are designed to solve one of the biggest challenges with aligner treatment – creati ...

Solventum Corporation (NYSE:SOLV) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Kevin Moran - SVP, IR Bryan Hanson - CEO Wayde McMillan - CFO Conference Call Participants Travis Steed - Bank of America Patrick Wood - Morgan Stanley Vik Chopra - Wells Fargo David Roman - Goldman Sachs Rick Wise - Stifel Ryan Zimmerman - BTIG Jason Bednar - Piper Sandler Chris Senyek - Wolfe Research Operator Good afternoon. My name is Amy, and I will be your conference operator for today. ...

| --- | --- | --- | |---------------------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | © Solventum 2024. All rights reserved. Q3 FY24 earnings presentation November 7, 2024 | | | Forward-looking statements and use of document Forward-looking statements This presentation contains forward-looking information about Solventum's financial results and estimates and business prospects that involve substantial risks and uncertainties. In parti ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $.01 Per Share SOLV New York Stock Exchange Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☐ Emerging growth company ☐ Common Stock, $0.01 par value per share 172,754,070 shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PU ...